Out to shake up PCSK9 market, Medicines Co boasts of pivotal PhIII win for inclisiran
The Medicines Company’s first pivotal Phase III results for inclisiran are in, and the biotech can’t wait to highlight the cholesterol-lowering potential of its long-acting drug.
Ahead of a data presentation of ORION-11 at next week’s European Society of Cardiology, The Medicines Company is putting out word that inclisiran — an RNAi therapeutic licensed from Alnylam that works by preventing PCSK9 from being synthesized in the liver — met all primary and secondary endpoints. The efficacy was “consistent with findings from Phase 1 and 2 studies” and the safety profile was “at least as favorable” as in previous Phase II studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.